These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32203092)

  • 1. The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.
    Bhargava R; Clark BZ; Carter GJ; Brufsky AM; Dabbs DJ
    Mod Pathol; 2020 Aug; 33(8):1563-1570. PubMed ID: 32203092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
    Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing: A Value Study.
    Bhargava R; Clark BZ; Dabbs DJ
    Am J Clin Pathol; 2019 Feb; 151(3):316-323. PubMed ID: 30395177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
    Turner BM; Skinner KA; Tang P; Jackson MC; Soukiazian N; Shayne M; Huston A; Ling M; Hicks DG
    Mod Pathol; 2015 Jul; 28(7):921-31. PubMed ID: 25932962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
    Hou Y; Tozbikian G; Zynger DL; Li Z
    Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX
    Turner BM; Gimenez-Sanders MA; Soukiazian A; Breaux AC; Skinner K; Shayne M; Soukiazian N; Ling M; Hicks DG
    Cancer Med; 2019 Aug; 8(9):4176-4188. PubMed ID: 31199586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
    Bhargava R; Esposito NN; OʹConnor SM; Li Z; Turner BM; Moisini I; Ranade A; Harris RP; Miller DV; Li X; Moosavi H; Clark BZ; Brufsky AM; Dabbs DJ
    Mod Pathol; 2021 Jan; 34(1):77-84. PubMed ID: 32661297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
    Hou Y; Zynger DL; Li X; Li Z
    Am J Clin Pathol; 2017 Aug; 148(2):167-172. PubMed ID: 28898988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX
    Turner BM; Finkelman BS; Hicks DG; Numbereye N; Moisini I; Dhakal A; Skinner K; Sanders MAG; Wang X; Shayne M; Schiffhauer L; Katerji H; Zhang H
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
    Farrugia DJ; Landmann A; Zhu L; Diego EJ; Johnson RR; Bonaventura M; Soran A; Dabbs DJ; Clark BZ; Puhalla SL; Jankowitz RC; Brufsky AM; Lembersky BC; Ahrendt GM; McAuliffe PF; Bhargava R
    Mod Pathol; 2017 Aug; 30(8):1078-1085. PubMed ID: 28548119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
    Sughayer M; Alaaraj R; Alsughayer A
    Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.
    Robertson SJ; Ibrahim MFK; Stober C; Hilton J; Kos Z; Mazzarello S; Ramsay T; Fergusson D; Vandermeer L; Mallick R; Arnaout A; Dent SF; Segal R; Sehdev S; Gertler S; Hutton B; Clemons M
    J Eval Clin Pract; 2019 Apr; 25(2):196-204. PubMed ID: 30672056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
    Klein ME; Dabbs DJ; Shuai Y; Brufsky AM; Jankowitz R; Puhalla SL; Bhargava R
    Mod Pathol; 2013 May; 26(5):658-64. PubMed ID: 23503643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.
    Robertson SJ; Pond GR; Hilton J; Petkiewicz SL; Ayroud Y; Kos Z; Gravel DH; Stober C; Vandermeer L; Arnaout A; Clemons M
    Clin Breast Cancer; 2020 Feb; 20(1):61-67. PubMed ID: 31551182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologist's health-care value in the triage of Oncotype DX
    Dabbs DJ; Clark BZ; Serdy K; Onisko A; Brufsky AM; Smalley S; Perkins S; Bhargava R
    Histopathology; 2018 Oct; 73(4):692-700. PubMed ID: 29920746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer.
    de Lima MAG; Clemons M; Van Katwyk S; Stober C; Robertson SJ; Vandermeer L; Fergusson D; Thavorn K
    J Eval Clin Pract; 2020 Jun; 26(3):889-892. PubMed ID: 31287198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score.
    Li H; Wang J; Li Z; Dababneh M; Wang F; Zhao P; Smith GH; Teodoro G; Li M; Kong J; Li X
    Front Med (Lausanne); 2022; 9():886763. PubMed ID: 35775006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers.
    Walts AE; Mirocha JM; Bose S
    Breast J; 2018 Nov; 24(6):951-956. PubMed ID: 30230113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
    Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.